A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
Brent A. Williams(Mayo Clinic), Armand Keating(University of Toronto), Bertrand Routy(Princess Margaret Cancer Centre), Arjun Law(Princess Margaret Cancer Centre), Vikas Gupta(Princess Margaret Cancer Centre), A. Chaboureau(Princess Margaret Cancer Centre), Neal denHollander(University Health Network), Xinghua Wang(Princess Margaret Cancer Centre), Sowmya Viswanathan(Princess Margaret Cancer Centre)
Cited by 187
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
|Science|2020|382